Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Asset Growth Recovery in ProgressRecovering
Percentile Rank44
3Y CAGR-15.9%
5Y CAGR+5.3%
Year-over-Year Change
Year-over-year total asset growth rate
3Y CAGR
-15.9%/yr
vs +7.5%/yr prior
5Y CAGR
+5.3%/yr
Recent deceleration
Acceleration
-23.3pp
Decelerating
Percentile
P44
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 5.15% |
| Q3 2025 | 3.43% |
| Q2 2025 | 5.05% |
| Q1 2025 | 1.54% |
| Q4 2024 | 1.32% |
| Q3 2024 | 10.47% |
| Q2 2024 | -15.83% |
| Q1 2024 | 5.22% |
| Q4 2023 | 4.62% |
| Q3 2023 | 6.77% |
| Q2 2023 | 7.25% |
| Q1 2023 | 4.54% |
| Q4 2022 | 8.65% |
| Q3 2022 | 7.21% |
| Q2 2022 | 9.30% |
| Q1 2022 | 6.13% |
| Q4 2021 | 6.45% |
| Q3 2021 | 3.25% |
| Q2 2021 | 0.88% |
| Q1 2021 | 3.09% |
| Q4 2020 | 3.98% |
| Q3 2020 | 10.62% |
| Q2 2020 | 14.88% |
| Q1 2020 | 6.91% |
| Q4 2019 | 10.70% |
| Q3 2019 | 6.84% |
| Q2 2019 | 7.49% |
| Q1 2019 | 4.76% |
| Q4 2018 | 35.17% |
| Q3 2018 | 6.58% |
| Q2 2018 | 9.67% |
| Q1 2018 | 11.48% |
| Q4 2017 | 10.87% |
| Q3 2017 | -2.66% |
| Q2 2017 | 11.50% |
| Q1 2017 | 1.83% |
| Q4 2016 | 11.09% |
| Q3 2016 | 2.19% |
| Q2 2016 | 2.45% |
| Q1 2016 | -0.37% |